In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific’s Taxus Element

This article was originally published in The Gray Sheet

Executive Summary

Enrollment begins for the PERSEUS clinical trial of Boston Scientific's third-generation paclitaxel-eluting stent July 13. The platinum chromium Taxus Element features thinner struts, more flexibility and a lower profile than previous Taxus models, the firm says. The PERSEUS program includes two components. The 1,264-patient Workhorse study will compare Taxus Element with Taxus Express2 in coronary lesions 2.75 to 4.0 millimeters in length. The primary endpoint is target lesion failure at 12 months. The second component is the 223-patient Small Vessel study comparing Taxus Element with a historical control in coronary lesions 2.25 to 2.75 millimeters long. The primary endpoint is in-stent late loss at nine months...

You may also be interested in...



3D Carbon Partners With Resolution Medical To Produce More Than 1 Million Nasal Swabs A Week

Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.

ACC 2020: Medtronic’s Evolut TAVR Works In Low-Risk Bicuspid Study

Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.

COVID-19 Will Spur Decentralized and Hybrid Trials – Novartis Hails Digital Investment

The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.

UsernamePublicRestriction

Register

MT025040

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel